PerkinElmer

The assay can be used to pool up to five specimens collected from individuals suspected of having COVID-19 or from asymptomatic patients.

According to some analysts, the selloff in IVD company shares may be an overreaction, and SARS-CoV-2-related testing will be needed for some time in the future. 

The quantitative kit applies a recombinant S1 subunit of the coronavirus spike protein to detect IgG antibodies against the coronavirus.

The reissued EUA is for the qualitative detection of nucleic acid from SARS-CoV-2 in human oropharyngeal swab, nasopharyngeal swab, and anterior nasal swab specimens.

COVID-19-related business contributed $288 million in revenues during the quarter, offsetting a 6 percent year-over-year decline in non-COVID-19-related revenues.

The test is designed to save resources by testing for the four viruses in one test using single nasopharyngeal, oropharyngeal, or nasal swab samples.

News items for the in vitro diagnostic industry for the week of Oct. 19, 2020.

News items for the in vitro diagnostics industry for the week of Oct. 12, 2020.

PerkinElmer will provide biochemical and genetic testing to support BioMarin's testing program aimed at Batten disease and mucopolysaccharidosis disorders.